The chelating agent contains the active ingredient Deferasirox, which has a high affinity for iron and is indicated for the treatment of chronic post-transfusion and non-transfusion iron overload.
 
 The drug was registered on November 16, 2023 and is currently available in strengths of 90 mg, 180 mg and 360 mg. The first batch of the drug in the volume of more than 1500 packs was released at the end of 2023. In the first half of March 2024 it is planned to release the second batch of the drug in the volume of about 1000 packs.
 
 The drug is manufactured at the plant of the Pharmasyntez Group of Companies in Irkutsk in the Solid Dosage Form Department, which is equipped with modern equipment. The product is manufactured in strict compliance with GMP standards.